3,6-disubstituted azabicyclo [3.1.0] hexane derivatives...

Details 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives... 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives...

2002-07-08

2008-07-15

Anderson, Rebecca L (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S515000

Reexamination Certificate

active

07399779

ABSTRACT:
This invention generally relates to the derivatives of novel 3,6 disubstituted azabicyclo[3.1.0]hexanes. The compounds of this invention are muscarinic receptor antagonists which are useful, inter-alia for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.

REFERENCES:
patent: 2490714 (1949-12-01), Searle
patent: 3176019 (1965-03-01), Campbell et al.
patent: 5001160 (1991-03-01), McPherson et al.
patent: 5164402 (1992-11-01), Brighty
patent: 5281601 (1994-01-01), Cross et al.
patent: 5397800 (1995-03-01), Alker et al.
patent: 5948792 (1999-09-01), Tsuchiya et al.
patent: 6130232 (2000-10-01), Mase et al.
patent: 6174900 (2001-01-01), Okada et al.
patent: 6313312 (2001-11-01), Banks et al.
patent: 2155320 (1993-08-01), None
patent: 0 325 571 (1989-07-01), None
patent: 0 388 054 (1990-09-01), None
patent: 0 413 455 (1991-02-01), None
patent: 0 613 232 (1994-08-01), None
patent: 0 801 067 (1997-10-01), None
patent: 0 823 423 (1998-02-01), None
patent: 0 863 141 (1998-09-01), None
patent: 940540 (1963-10-01), None
patent: 92921/1994 (1994-04-01), None
patent: 135958/1994 (1994-05-01), None
patent: WO 91/09013 (1991-06-01), None
patent: WO 93/16018 (1993-08-01), None
patent: WO 93/16048 (1993-08-01), None
patent: WO 96/33973 (1996-10-01), None
patent: WO 97/45414 (1997-12-01), None
patent: WO 98/05641 (1998-02-01), None
patent: WO 98/29402 (1998-07-01), None
patent: WO 98/53814 (1998-12-01), None
patent: WO 01/42212 (2001-06-01), None
patent: WO 01/42213 (2001-06-01), None
patent: WO 01/90081 (2001-11-01), None
patent: WO 02/00652 (2002-01-01), None
patent: WO 02/04402 (2002-01-01), None
patent: WO 02/06241 (2002-01-01), None
patent: WO 02/51841 (2002-07-01), None
patent: WO 02/053564 (2002-07-01), None
patent: WO 2004/004629 (2004-01-01), None
patent: WO 2004/005252 (2004-01-01), None
patent: WO 2004/014363 (2004-02-01), None
patent: WO 2004/014853 (2004-02-01), None
patent: WO 2004/018422 (2004-03-01), None
patent: WO 2004/052857 (2004-06-01), None
patent: WO 2004/056767 (2004-07-01), None
patent: WO 2004/056810 (2004-07-01), None
patent: WO 2004/056811 (2004-07-01), None
patent: WO 2004/089900 (2004-10-01), None
Morissette et al. Advanced Drug Delivery Reviews 2004, 56, 275-300.
Wess et al. Life Sciences 2003, 72, 2047-2054.
O'Neill, M. Drug Discovery Today Oct. 2005, 10(20), 1338.
Michel et al. Naunyn-Schmiedeberg's Arch Pharmacol 2006, 374, 79-85.
Latifpour et al. The Journal of Pharmacology and Experimental Therapeutics 1989, 249(1), 81-88.
Carrier et al. The Journal of Pharmacology and Experimental Therapeutics 1987, 242(2), 531-535.
Ahren et al. Diabetologia 1996, 39, 383-390.
Abrams et al. British Journal of Pharmacology 2006, 148, 565-578.
de Groat and Yoshimura, “Pharmacology of the Lower Urinary Tract”,Annual Review of Pharmacology and Toxicology, 41:691-721 (2001).
Cheng and Prusoff, “Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction”,Biochemical Pharmacology, 22:3099-3108 (1973).
Birdsall et al., “Muscarinic receptors; it's a knockout”,Trends in Pharmacological Sciences, 22(5):215-219 (2001).
Brighty et al., “Synthesis of (1α,5α,6α)-6-Amino-3-azabicyclo[3.1.0]hexane, a Novel Achiral Diamine”,Synlett, 1097-1099 (1996).
Braish et al., “Construction of the (1α,5α,6α)-6-Amino-3-azabicyclo[3.1.0]hexane Ring System”,Synlett, 1100-1102 (1996).
Chapple, “Muscarinic receptor antagonists in the treatment of overactive bladder”,Urology, 55(Suppl. 5A):33-46 (2000).
Eglen et al., “Muscarinic receptor ligands and their theraputic potential”,Current Opinion in Chemical Biology, 3:426-432 (1999).
Eglen et al., “Theraputic opportunities from muscarinic receptor research”,Trends in Pharmacological Sciences, 22(8):409-414 (2001).
Felder et al., “Theraputic Opportunities for Muscarinic Receptors in the Central Nervous System”,Journal of Medicinal Chemistry, 43(23):4333-4353 (2000).
Grover et al., “Chiral Mandelic Acid Template Provides a Highly Practical Solution for (S)-Oxybutynin Synthesis”,Journal of Organic Chemistry, 65:6283-6287 (2000).
Shacklett and Smith, “The Preparation of Substituted Benzilic Acids”,Journal of the American Chemical Society, 75:2654-2657 (1953).
Sagara et al., “Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M3Antagonist Discriminating against the Other Receptor Subtypes”,Journal of Medicinal Chemistry, 45:984-987 (2002).
Nkpa and Chedekel, “Mechanistic Studies on the Addition of Cysteine to 3,4-Dihydroxyphenylalanine”,Journal of Organic Chemistry, 46:213-215 (1981).
Kadin and Cannon, “Esters ofN-Methyl-3-hydroxypiperidine Having Psychotomimetic Activity. II”,Journal of Organic Chemistry, 27:240-245 (1962).
Broadley and Kelly, “Muscarinic Receptor Agonists and Antagonists”,Molecules, 6:142-193 (2001).
Moriya et al., “Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland”,Life Sciences, 64(25):2351-2358 (1999).
Kubo et al., “Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor”,Nature, 323(2):411-416 (1986).
Bonner et al., “Identification of a Family of Muscarinic Acetylcholine Receptor Genes”,Science, 237:527-531 (1987).
Steers, “The future direction of neuro-urology drug research”,Current Opinion in CPNS Investigational Drugs, 2(3):268-282.
Steers, Barrot, Wein, “Voiding dysfunction: diagnosis classification and management”, In:Adult and Pediatric Urology, ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996).
Weinstock et al., “A General, One-Step Synthesis of α-keto Esters”,Synthetic Communications, 11(12):943-946 (1981).
Vogel's textbook, “Practical Organic Chemistry” 1046-1047 (5th Ed.).
“Design of prodrugs”, ed. H. Bundgaard, Elsevier (1985).

Affiliated with

Also associated with

Rating

3,6-disubstituted azabicyclo [3.1.0] hexane derivatives... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3967828